Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
12
¥100 millionWording
Conditional
How definitive the wording is.This transaction
中国生産子会社の設立Disclosing companyMANI,INC.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
TimelineThe spacing between the points is proportional to the actual number of days.White points represent dates designated as scheduled dates in the document.
Target company
中国市場向け眼科ナイフ等の製造
Location Foshan, Guangdong Province, People's Republic of ChinaShare capital 32 百万人民元Date of incorporation 2026 年 4 月（予定）
Impact on Business Performance
今回の中国工場新設により、当社は総額 12 億円の設備投資等を予定しております。2026 年 8 月期設備投資計画および連結業績見通しにその影響を織り込んでおりますが、開示すべき事項が発生した場合には速やかに開示いたします。
Procedures and assumptions
Management structure after acquisition名称（仮）：馬尼医療機器（佛山市）有限公司、代表者：焦炜然（Jiao Weiran）。従業員の処遇については Not disclosed
| Item | Details |
|---|---|
| Transaction name | 中国生産子会社の設立 |
| Name of the Subject Company | 馬尼医療機器（佛山市）有限公司（名称（仮）） |
| Business Description of the Subject Company | 中国市場向け眼科ナイフ等の製造 |
| Location of the Subject Company | Foshan, Guangdong Province, People's Republic of China |
| Capital Stock of the Subject Company | 32 百万人民元 |
| Date of Establishment of the Subject Company | 2026 年 4 月（予定） |
| Voting rights ownership percentage | After 100% (before not disclosed) |
| Impact on Business Performance | 今回の中国工場新設により、当社は総額 12 億円の設備投資等を予定しております。2026 年 8 月期設備投資計画および連結業績見通しにその影響を織り込んでおりますが、開示すべき事項が発生した場合には速やかに開示いたします。 |
| Date of board resolution | 14 January 2026 |
| Execution Date / Effective Date | 2026 年 4 月（設立予定）、2028 年 3 月（量産開始予定） |
| Management structure after acquisition | 名称（仮）：馬尼医療機器（佛山市）有限公司、代表者：焦炜然（Jiao Weiran）。従業員の処遇については Not disclosed |
Items this document does not state (21)
Counterparty nameNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.中国市場で強まる国産品優遇政策に対応し、現地生産によって中国市場での既存シェアを維持するとともに、顧客ニーズへの対応と競争力の強化を図るため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.